Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer

Davina Gale; Katrin Heider; Andrea Ruiz-Valdepeñas; Sophie Hackinger; Marc D. Perry; Giovanni Marsico; Viona Rundell; Jerome Wulff; Geeta G. Sharma; H. Knock; José Luís Castedo; Wendy N. Cooper; Heng Zhao; Christopher G. Smith; Sumedha Garg; S. Anand; Karen Howarth; David Gilligan; Susan Harden; Doris M. Rassl; Robert C. Rintoul; Nitzan Rosenfeld

doi:10.1016/j.annonc.2022.02.007

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

ctDNA detection after initial treatment of patients with early-stage NSCLC using sensitive patient-specific assays has potential to identify patients who may benefit from further therapeutic intervention.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gale et al. (2022) studied this question.

synapsesocial.com/papers/69d72b4866e6af6209f5081c https://doi.org/10.1016/j.annonc.2022.02.007

View Full Paper

Ask AI

Bookmark

Share

Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading